Clinical Scenarios: Improving Awareness of PNH in Primary Care Settings – An In the Clinic Activity



This activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.


Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immunologic disorder that leads to the destruction of red blood cells through the complement cascade. Three complement inhibitors (CIs) are now available to treat this disorder that typically affects young adults during their most productive years and results in a high early mortality rate if not treated appropriately. With CIs, patients with PNH can now expect to live a relatively normal lifespan, but only if physicians and other members of the primary care team know how to recognize the signs and symptoms of this disease so patients can be referred to hematologist experts in PNH.

Join expert Dr. Carlos de Castro III to find out what primary care health professionals need to know about when PNH should be suspected, how it is diagnosed and treated, and how to evaluate and monitor treatment response. This video-based activity includes an informative slide presentation and two in-depth clinical case studies.


Carlos M. de Castro III, MD
Professor of Medicine
Department of Medicine
Duke University
Durham, North Carolina

Release date: January 31, 2023
Expiration date: January 31, 2024
Estimated time to complete activity: 60 minutes

This educational activity has been designed to meet the needs of physicians in internal medicine, primary care, and family medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with PNH.


Upon completion of this educational activity, participants should be able to:

  • Identify symptoms, disease manifestations, and assessment criteria that indicate the need for PNH testing and referral to a hematology expert
  • Describe the pathogenesis of PNH, the complement cascade, and complement inhibitors
  • Devise a strategy for monitoring patients with PNH who are being treated with complement inhibitors

There are no fees for participating and receiving CME credit for this activity. During the period of January 31, 2023 through January 31, 2024 participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 60% or better.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Carlos M. de Castro III, MD
Consultant: Alexion, Apellis, Biocryst
Data Safety Monitoring Board: Regeneron
Researcher: Apellis
Speaker: Apellis
Steering Committee: Novartis

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest